VEGFA and neoplasm: Antiangiogenic therapy cut off the nutrient and oxygen supply to the tumor by inhibiting multi-targeted angiogenic factors in the TME such as VEGF, thus preventing tumor angiogenesis (11); at the same time, they can reverse the state of immunosuppression in the TME, and promote the infiltration and activation of immune cells, thus enhancing the immune response to the tumor (12).